AIM ImmunoTech Inks Pancreatic Cancer Clinical Research Deals With AstraZeneca, Erasmus
LONDON (dpa-AFX) - Immuno-pharma company AIM ImmunoTech Inc. (AIM) announced Tuesday it has entered into an external sponsored collaborative clinical…
Echtzeit-Aktienkurs AIM Immunotech Inc.
Bid:
Ask:
Nachrichten zur AIM Immunotech Inc. Aktie
Form 8-K AIM ImmunoTech Inc. For: Jan 13
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
Research collaboration will evaluate the potential of AIMs Ampligen® (rintatolimod) in combination with AstraZenecas Imfinzi (durvalumab) for the treatment of…
AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer
Accomplished scientist with a diverse range of skills from general wet lab technique to company-wide operations management Accomplished scientist with…
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects
Intranasal administration of Ampligen demonstrated to be well-tolerated...…
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022
OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”),…
AIM ImmunoTech Posts Wider 3Q Loss Amid Higher Costs
AIM ImmunoTech Posts Wider 3Q Loss Amid Higher Costs...…
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones...…
AIM ImmunoTech soars on FDA orphan drug tag for Ampligen to treat Ebola virus disease
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity currently being evaluated for the treatment of globally important cancers, viral…
AIM Immunotech says court denies activist request on board nominees
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions
Company expects to commence patient enrollment and dosing in Q1 2023 Company expects to commence patient enrollment and dosing in…
NA Proactive news snapshot: Westwater Resources, X1 Esports and Entertainment, Aftermath Silver, Royal Helium, AIM ImmunoTech, Gratomic, Québec Nickel...
Um den gesamten Artikel unter proactiveinvestors.com zu lesen, klicken Sie bitte auf die Überschrift...…
AIM ImmunoTech receives regulatory go-ahead for Phase 2 trial of investigational drug Ampligen for patients with post-COVID conditions
Um den gesamten Artikel unter proactiveinvestors.com zu lesen, klicken Sie bitte auf die Überschrift...…
AIM ImmunoTech Gets FDA Clearance for Post-Covid Drug Study
AIM ImmunoTech Gets FDA Clearance for Post-Covid Drug Study...…
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions
Company expects to commence patient enrollment and dosing in Q1 2023 Company expects to commence patient enrollment and dosing in…